Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials.
Am J Respir Crit Care MedSep 1, 2026
Dave Singh, Rianne Stacey, David M G Halpin et al.
✦ AI-curated · Sources linked
In 30 seconds
This study analyzed data from phase 3 clinical trials to define disease stability in chronic obstructive pulmonary disease (COPD) as a composite endpoint. Stability was characterized by the absence of moderate/severe exacerbations and no worsening in COPD Assessment Test (CAT) and FEV1. Achieving stability at week 28 was associated with a 45.7% reduction in moderate/severe exacerbations and a 51.7% reduction in all-cause mortality thereafter.
Key findings
- Stability was achieved by 22% of patients with FF/UMEC/VI in IMPACT at week 52.
- Stability was achieved by 46% of patients in FULFIL at week 24.
- Patients achieving stability had a 45.7% reduction in moderate/severe exacerbations after week 28.
- The mean posterior probability of stability was 25.60% at week 52 with FF/UMEC/VI.
Why it matters
Defining and achieving disease stability in COPD can guide treatment strategies and improve patient outcomes, particularly in reducing exacerbations and mortality risk.